GlassScriptPhysician profile
Biren Patel
NPI 1992295349
$1,330.50
in general payments reported to CMS, 2019-2025
15 companies · $746 in 2025
The $746 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $280 · 2023: $122 · 2024: $182 · 2025: $746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,050.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aop Health US, LLC | $379.90 | 2025 | Rapiblyk |
| Astrazeneca Pharmaceuticals LP | $156.15 | 2022 | |
| Amgen INC. | $145.21 | 2022-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $121.84 | 2022-2025 | Lithovue Empower, General - Therapies |
| Novartis Pharmaceuticals Corporation | $105.95 | 2023-2025 | |
| Irhythm Technologies, INC. | $95.20 | 2024 | Zio Monitor, Zio Xt Patch |
| Merck Sharp & Dohme LLC | $87.53 | 2022-2025 | Verquvo |
| Pfizer INC. | $61.75 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.35 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.33 | 2025 | Jardiance |
| Esperion Therapeutics, INC. | $30.75 | 2023-2024 | Nexletol |
| Stryker Corporation | $24.67 | 2024 | Nico Brainpath |
| Glaxosmithkline, LLC. | $17.98 | 2025 | Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $17.56 | 2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $13.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Biren Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.